Monoclonal antibodies in severe asthma: outcomes from real-world data.

3.3 Multiple comparisons among different monoclonal antibodies Nominally significant differences were observed in the following variables: baseline exacerbations per year, baseline hospital admissions per year, and eosinophil levels after 12 months of monoclonal antibody treatment ( Table 3 ).

also in 7,732 other papers